Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone202-734-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$193.12 million
Profitability
Miscellaneous
Employees273
OptionableOptionable
Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions
What is Vanda Pharmaceuticals' stock symbol?
Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
How were Vanda Pharmaceuticals' earnings last quarter?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings results on Wednesday, February, 13th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.22. The biopharmaceutical company earned $53.04 million during the quarter, compared to analysts' expectations of $51.56 million. Vanda Pharmaceuticals had a return on equity of 10.03% and a net margin of 13.05%. The company's revenue for the quarter was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.04) earnings per share. View Vanda Pharmaceuticals' Earnings History.
When is Vanda Pharmaceuticals' next earnings date?
What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?
Vanda Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, February, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $215-225 million, compared to the consensus revenue estimate of $246.66 million.
What price target have analysts set for VNDA?
9 Wall Street analysts have issued 1 year price objectives for Vanda Pharmaceuticals' stock. Their forecasts range from $21.00 to $52.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $36.00 in the next year. This suggests a possible upside of 70.5% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.
What is the consensus analysts' recommendation for Vanda Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals.
What are Wall Street analysts saying about Vanda Pharmaceuticals stock?
Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
- 1. Stifel Nicolaus analysts commented, "We believe shares of VNDA should find some relief after the recent volatility (shares down -26% since 2/5 vs. S&P 500 which is up +1%) which has largely been driven by the news of the partial clinical hold (PCH) on tradipitant and the unsealed whistleblower lawsuit, but also the fact VNDA didn’t issue preliminary results at the JP Morgan conference in January which it had normally done in years past. We think the 4Q results and 2019 guidance should get investors more comfortable that VNDA’s base business (Hetlioz and Fanapt) continues to be generally healthy with a decent growth profile." (2/14/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and reduce our PT to $26 from $30 for VNDA based on lowered 2019 revenue projections. On Wednesday, Vanda reported 4Q18 revenues of $32.4M for HETLIOZ and $20.6M for Fanapt, which were in line with our estimates. Vanda ended 4Q18 with cash of ~$257M, sufficient to fund operations through clinical milestones such as the first P3 study of tradi’ in atopic dermatitis. Although we project YoY growth for HETLIOZ in 2019, we do not view it as a source of underappreciated value. However if label expansion into SMS is achieved (pending FDA input on capital efficient next steps), this could prove to be a tractable, growth driving opportunity." (2/14/2019)
- 3. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (11/17/2018)
Has Vanda Pharmaceuticals been receiving favorable news coverage?
News articles about VNDA stock have trended positive recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future.
Who are some of Vanda Pharmaceuticals' key competitors?
Some companies that are related to Vanda Pharmaceuticals include Taro Pharmaceutical Industries (TARO), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Evotec (EVTCY), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT) and Ligand Pharmaceuticals (LGND).
Who are Vanda Pharmaceuticals' key executives?
Vanda Pharmaceuticals' management team includes the folowing people:
- Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)
- Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)
- Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)
- Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)
- Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.
Who are Vanda Pharmaceuticals' major shareholders?
Vanda Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.73%), Macquarie Group Ltd. (4.69%), First Manhattan Co. (1.79%), Northern Trust Corp (1.33%), Prudential Financial Inc. (1.28%) and Bank of New York Mellon Corp (1.21%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Institutional Ownership Trends for Vanda Pharmaceuticals.
Which major investors are selling Vanda Pharmaceuticals stock?
VNDA stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Prudential Financial Inc., QS Investors LLC, Stonepine Capital Management LLC, BlackRock Inc., Arizona State Retirement System, Two Sigma Advisers LP and Barclays PLC. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.
Which major investors are buying Vanda Pharmaceuticals stock?
VNDA stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Acadian Asset Management LLC, Candriam Luxembourg S.C.A., First Manhattan Co., First Trust Advisors LP, Canada Pension Plan Investment Board, Algert Global LLC and PNC Financial Services Group Inc.. View Insider Buying and Selling for Vanda Pharmaceuticals.
How do I buy shares of Vanda Pharmaceuticals?
Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vanda Pharmaceuticals' stock price today?
One share of VNDA stock can currently be purchased for approximately $21.11.
How big of a company is Vanda Pharmaceuticals?
Vanda Pharmaceuticals has a market capitalization of $1.11 billion and generates $193.12 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.
What is Vanda Pharmaceuticals' official website?
How can I contact Vanda Pharmaceuticals?
Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]
MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
